quinacrine has been researched along with Joint Diseases in 2 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Joint Diseases: Diseases involving the JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1)." | 1.48 | Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. ( Agesta, N; Martinez-Zapico, A; Ortego-Centeno, N; Porta, S; Ríos, R; Ruiz-Irastorza, G; Ugarte, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ugarte, A | 1 |
| Porta, S | 1 |
| Ríos, R | 1 |
| Martinez-Zapico, A | 1 |
| Ortego-Centeno, N | 1 |
| Agesta, N | 1 |
| Ruiz-Irastorza, G | 1 |
| Maroy, B | 1 |
2 other studies available for quinacrine and Joint Diseases
| Article | Year |
|---|---|
Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Topics: Adult; Antimalarials; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressi | 2018 |
[Effect of Collagenan on joint disease associated with collagenous colitis].
Topics: 4-Aminobenzoic Acid; Aminobenzoates; Chloroquine; Colitis; Collagen; Drug Combinations; Female; Huma | 1986 |